Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Minor: Monitoring Combined Effect of Balance and Strengthening Exercises on Static and Dynamic Balance in Elderly Populations Completed without a posted recruiting period South Valley UniversityNot applicable NCT06835413
  2. Minor: Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophysiological Measures With · Autism Spectrum Disorder (ASD) Trial completed University of New MexicoNot applicable NCT06495684
  3. Minor: Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study Primary completion pushed from Jun 2026 to Dec 2026 Azienda USL Reggio Emilia - IRCCSNot specified NCT06994182
  4. Minor: Bleximenib · Acute Leukemia (cAMeLot-1) Enrollment increased: 420 → 494 participants Janssen Research & Development, LLCPhase 1/2 NCT04811560
  5. Minor: ESCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents · Cancer Primary and study completion pushed from Dec 31, 2026 to Jan 31, 2027 Nemours Children's ClinicNot applicable NCT05294302
  6. Minor: Sacral ESP Block and Caudal Block in Pediatric Hypospadias Surgery Primary completion pushed from Sep 1, 2026 to Dec 1, 2026 TC Erciyes UniversityNot applicable NCT07619651
  7. Minor: Multi-Segmental Spinal Manual Therapy · Episodic Migraine Primary completion pushed from Nov 30, 2026 to Jan 20, 2027 Borna FarhoomandNot applicable NCT07774286
  8. Minor: Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery Primary completion pushed from Dec 2026 to Jun 2027 Duke UniversityNot applicable NCT07117708
  9. Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 240 → 265 locations SanofiPhase 3 NCT07184996
  10. Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 461 → 481 locations SanofiPhase 3 NCT07184931
  11. Minor: Symbiotic-GI-16 · PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer Trial sites expanded: 100 → 124 locations PfizerPhase 2/3 NCT07392892
  12. Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations AbbViePhase 3 NCT07772492
  13. Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations AbbViePhase 3 NCT07880756
  14. Minor: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Trial sites expanded: 200 → 209 locations Olema Oncology, Inc.Phase 3 NCT07085767
  15. Minor: Intravenous Anifrolumab · Systemic Lupus Erythematosus in Pediatric Participants Trial sites expanded: 103 → 111 locations AstraZenecaPhase 3 NCT05835310
  16. Minor: Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Trial sites expanded: 93 → 97 locations PfizerPhase 3 NCT05156398
  17. Minor: Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder Trial sites reduced: 62 → 56 locations GRIN Therapeutics, Inc.Phase 3 NCT07224581
  18. Minor: Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Trial sites expanded: 1 → 11 locations CellCentric Ltd.Phase 3 NCT07772024
  19. Minor: Pegozafermin · MASH and Fibrosis (ENLIGHTEN-Fibrosis) Trial sites expanded: 370 → 375 locations Hoffmann-La RochePhase 3 NCT06318169
  20. Minor: Maintenance Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 109 → 152 locations SanofiPhase 3 NCT07184944
  21. Minor: Rimegepant in Adults When Used · Chronic Migraine Trial sites expanded: 19 → 38 locations PfizerPhase 3 NCT07729462
  22. Minor: Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Trial sites reduced: 136 → 133 locations UCB Biopharma SRLPhase 3 NCT05076617
  23. Minor: Momelotinib · Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Trial sites expanded: 0 → 3 locations GlaxoSmithKlinePhase 2/3 NCT07569081
  24. Minor: Oral Levosimendan Trial sites expanded: 9 → 14 locations Tenax Therapeutics, Inc.Phase 3 NCT07436689
  25. Minor: Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Trial sites expanded: 184 → 198 locations PfizerPhase 1/2 NCT07421700